Massimiliano Cadamuro

Dr. Massimiliano Cadamuro

University of Padua, Padua, Italy

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2021 in Pathologica
Verified
Journal Article
Open access
PDF file
SSSamantha Sarcognato
Samantha Sarcognato
DSDiana Sacchi
Diana Sacchi
Matteo FassanMatteo Fassan
Matteo Fassan
LFLuca Fabris
Luca Fabris
MCMassimiliano Cadamuro
Massimiliano Cadamuro
MGMaria Guido
Maria Guido
Liver cancer represents the third leading cause of cancer-related death worldwide. Cholangiocarcinoma (CCA) is the second most common type of liver cancer after hepatocellular carcinoma, accounting for 10-15% of all primary liver malignancies. Both the incidence and mortality of CCA have been steadily increasing during the last decade. Moreover, most CCAs are diagnosed at an advanced stage, when therapeutic options are very limited. CCA may arise from any tract of the biliary system and it is classified into intrahepatic, perihilar, and distal CCA, according to the anatomical site of origin. This topographical classification also reflects distinct genetic and histological features, risk factors, and clinical outcomes. This review focuses on histopathology of CCA, its differential diagnoses, and its diagnostic pitfalls.

1 April 2019 in Journal of Hepatology
Verified
Journal Article
Closed access
MCMassimiliano Cadamuro
Massimiliano Cadamuro
SBSimone Brivio
Simone Brivio
JMJoachim Mertens
Joachim Mertens
MVMarta Vismara
Marta Vismara
AMAnja Moncsek
Anja Moncsek
LFLuca Fabris
Luca Fabris

15 March 2013 in Hepatology
Verified
Journal Article
Open access
PDF file
MCMassimiliano Cadamuro
Massimiliano Cadamuro
GNGiorgia Nardo
Giorgia Nardo
Stefano IndraccoloStefano Indraccolo
Stefano Indraccolo
LDLuigi Dall'Olmo
Luigi Dall'Olmo
LSLuisa Sambado
Luisa Sambado
MSMario Strazzabosco
Mario Strazzabosco
Cholangiocarcinoma (CCA) is characterized by an abundant stromal reaction. Cancer-associated fibroblasts (CAFs) are pivotal in tumor growth and invasiveness and represent a potential therapeutic target. To understand the mechanisms leading to CAF recruitment in CCA, we studied (1) expression of epithelial-mesenchymal transition (EMT) in surgical CCA specimens and CCA cells, (2) lineage tracking of an enhanced green fluorescent protein (EGFP)-expressing human male CCA cell line (EGI-1) after xenotransplantation into severe-combined-immunodeficient mice, (3) expression of platelet-derived growth factors (PDGFs) and their receptors in vivo and in vitro, (4) secretion of PDGFs by CCA cells, (5) the role of PDGF-D in fibroblast recruitment in vitro, and (6) downstream effectors of PDGF-D signaling. CCA cells expressed several EMT biomarkers, but not alpha smooth muscle actin (α-SMA). Xenotransplanted CCA masses were surrounded and infiltrated by α-SMA-expressing CAFs, which were negative for EGFP and the human Y-probe, but positive for the murine Y-probe. CCA cells were strongly immunoreactive for PDGF-A and -D, whereas CAFs expressed PDGF receptor (PDGFR)β. PDGF-D, a PDGFRβ agonist, was exclusively secreted by cultured CCA cells. Fibroblast migration was potently induced by PDGF-D and CCA conditioned medium and was significantly inhibited by PDGFRβ blockade with Imatinib and by silencing PDGF-D expression in CCA cells. In fibroblasts, PDGF-D activated the Rac1 and Cdc42 Rho GTPases and c-Jun N-terminal kinase (JNK). Selective inhibition of Rho GTPases (particularly Rac1) and of JNK strongly reduced PDGF-D-induced fibroblast migration. Conclusion: CCA cells express several mesenchymal markers, but do not transdifferentiate into CAFs. Instead, CCA cells recruit CAFs by secreting PDGF-D, which stimulates fibroblast migration through PDGFRβ and Rho GTPase and JNK activation. Targeting tumor or stroma interactions with inhibitors of the PDGF-D pathway may offer a novel therapeutic approach. (Hepatology 2013;53:1042–1053)

1 August 2007 in The American Journal of Pathology
Verified
Journal Article
Closed access
LFLuca Fabris
Luca Fabris
MCMassimiliano Cadamuro
Massimiliano Cadamuro
MGMaria Guido
Maria Guido
CSCarlo Spirli
Carlo Spirli
RFRomina Fiorotto
Romina Fiorotto
MSMario Strazzabosco
Mario Strazzabosco

20 April 2006 in Hepatology
Verified
Journal Article
Open access
PDF file
LFLuca Fabris
Luca Fabris
MCMassimiliano Cadamuro
Massimiliano Cadamuro
RFRomina Fiorotto
Romina Fiorotto
TRTania Roskams
Tania Roskams
CSCarlo Spirlì
Carlo Spirlì
MSMario Strazzabosco
Mario Strazzabosco
Liver involvement in autosomal dominant polycystic kidney disease (ADPKD) is characterized by altered remodeling of the embryonic ductal plate (DP) with presence of biliary cysts and aberrant portal vasculature. The genetic defect causing ADPKD has been identified, but mechanisms of liver cyst growth remain uncertain. To investigate the possible role of angiogenic mechanisms, we have studied the immunohistochemical expression of vascular endothelial growth factor (VEGF), angiopoietin–1 (Ang-1), angiopoietin-2 (Ang-2) and their receptors (VEGFR-1, VEGFR-2, Tie-2) in ADPKD, Caroli's disease, normal and fetal livers. In ADPKD and control livers Ang-1 and Ang-2 gene expression was studied by real-time-PCR. Effects of VEGF on cholangiocyte proliferation were studied by PCNA Western Blot in isolated rat cholangiocytes and by MTS assay in cultured cholangiocytes isolated from ADPKD patients and from an ADPKD mouse model (Pkd2WS25/−). Cholangiocytes were strongly positive for VEGF, VEGFR-1, VEGFR-2 and Ang-2 in ADPKD and Caroli, and also for Ang-1 and Tie-2 in ADPKD, similar to fetal ductal plate cells. VEGF stimulated proliferation in both normal and ADPKD cholangiocytes, but the effect was particularly evident in the latter. Ang-1 alone had no effect, but was synergic to VEGF. VEGF expression on cholangiocytes positively correlated with microvascular density. In conclusion , consistent with the immature phenotype of the cystic epithelium, expression of VEGF, VEGFRs, Ang-1 and Tie-2 is strongly upregulated in cholangiocytes from polycystic liver diseases. VEGF and Ang-1 have autocrine proliferative effect on cholangiocyte growth and paracrine effect on portal vasculature, thus promoting the growth of the cysts and their vascular supply. Supplementary material for this article can be found on the HEPATOLOGY website ( http://interscience.wiley.com/jpages/0270-9139/suppmat/index.html ). (Hepatology 2006;43:1001–1012.)

6 March 2019 in Liver International
Verified
Journal Article
Closed access
PDF file
Rocio MaciasRocio Macias
Rocio Macias
Miroslaw KornekMiroslaw Kornek
Miroslaw Kornek
PRPedro M. Rodrigues
Pedro M. Rodrigues
NPNuno A. Paiva
Nuno A. Paiva
RCRui E. Castro
Rui E. Castro
Jesús BañalesJesús Bañales
Jesús Bañales